The effects of ezetimibe on malondialdehyde-modified low-density lipoprotein in abnormal glucose tolerance patients with coronary artery disease

INTERVENTION: Administration of atorvastatin 20mg in the first 3 months, followed by the administration of atorvastatin 10mg and ezetimibe 10mg Administration of atorvastatin 10mg and ezetimibe 10mg in the first 3 months, followed by the administration of atorvastatin 20mg CONDITION: Coronaty artery disease with diabetes, including impaired glucose torelance PRIMARY OUTCOME: Change and percent change in MDA‐LDL SECONDARY OUTCOME: Change and percent change in TC, LDL‐C, TG, and HDL‐C.; Change and percent change in HbA1c INCLUSION CRITERIA: 1) Patients who have a history of following coronary heart diseases; CABG or PCI was performed more than 6 months before >= 50% coronary artery stenosis according to the ACC/AHA classification was found by CAG 2) Diabetic patients under treatment or patients who diagnosed with diabetic (inclucing IGT; 2‐hour plasma/serum glucose level: 140mg/dL to 199mg/dL) at 75g oral glucose tolerance test 3) Patients who take atorvastatin 10mg more than 3 months 4) Patients who are judged to require the more lipid‐lowering therapy